Search
Cardiolipin Biosynthesis CL(i-15:0/i-18:0/20:0/20:0)
smpdb.ca/view/SMP0465040MetabolicCardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.
Cardiolipin Biosynthesis CL(a-15:0/i-19:0/20:0/20:0)
smpdb.ca/view/SMP0468866MetabolicCardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.
Cardiolipin Biosynthesis CL(i-13:0/i-19:0/20:0/20:0)
smpdb.ca/view/SMP0472975MetabolicCardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.
Cardiolipin Biosynthesis CL(i-15:0/i-19:0/20:0/20:0)
smpdb.ca/view/SMP0475028MetabolicCardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.
Cardiolipin Biosynthesis CL(8:0/i-20:0/i-20:0/24:0)
smpdb.ca/view/SMP0475553MetabolicCardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.
Cardiolipin Biosynthesis CL(8:0/i-20:0/i-20:0/25:0)
smpdb.ca/view/SMP0475559MetabolicCardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.
3-ketoacyl-CoA thiolase
go.drugbank.com/bio_entities/BE0004257TargetPseudomonas fragiCatalyzes the final step of fatty acid oxidation in which acetyl-CoA is released and the CoA ester of a fatty acid two carbons shorter is formed.
Synonyms: Fatty acid oxidation complex subunit betaOveporexton
go.drugbank.com/drugs/DB21680Approved[L64069] The FDA approved oveporexton on August 5, 2026 for the treatment of narcolepsy type 1 (narcolepsy with cataplexy) in adults. … Oveporexton is an orally administered orexin receptor 2 (OX2R) agonist used to treat narcolepsy type 1 (NT1).
Dengue virus serotype 2
go.drugbank.com/drugs/DB22665Approved[L53368] Qdenga was approved for use in the European Union in December 2022.[L53373]
Dengue virus serotype 3
go.drugbank.com/drugs/DB22666Approved[L53368] Qdenga was approved for use in the European Union in December 2022.[L53373]